阿替唑单抗
医学
肿瘤科
化疗
内科学
无症状的
临床研究阶段
阶段(地层学)
癌症
免疫疗法
彭布罗利珠单抗
古生物学
生物
作者
Ernest Nadal,Bartomeu Massuti,G. Huidobro,Rui E. Castro,Anna Estival,Julio Mosquera,Ian D. Sullivan,Enriqueta Felip,Agustín Blasco,M. Guirado,Marta Simó,Ernesto C. Pereira,Vicente Navarro,Jordi Bruna
标识
DOI:10.1016/j.jtho.2021.08.062
摘要
Patients (pts) with untreated brain metastases (BM) have been excluded or underrepresented in clinical trials conducted in the first line setting evaluating the combination of chemotherapy plus immune checkpoint inhibitors. Here, we investigated the safety and efficacy of chemotherapy plus atezolizumab in NSCLC pts with asymptomatic untreated BM.
科研通智能强力驱动
Strongly Powered by AbleSci AI